Modulatory effects of the piccolo genotype on emotional memory in health and depression

PLoS One. 2013 Apr 19;8(4):e61494. doi: 10.1371/journal.pone.0061494. Print 2013.

Abstract

Major depressive disorder (MDD) has been associated with biased memory formation for mood-congruent information, which may be related to altered monoamine levels. The piccolo (PCLO) gene, involved in monoaminergic neurotransmission, has previously been linked to depression in a genome-wide association study. Here, we investigated the role of the PCLO risk allele on functional magnetic resonance imaging (MRI) correlates of emotional memory in a sample of 89 MDD patients (64 PCLO risk allele carriers) and 29 healthy controls (18 PCLO risk allele carriers). During negative word encoding, risk allele carriers showed significant lower activity relative to non-risk allele carriers in the insula, and trend-wise in the anterior cingulate cortex and inferior frontal gyrus. Moreover, depressed risk allele carriers showed significant lower activity relative to non-risk allele carriers in the striatum, an effect which was absent in healthy controls. Finally, amygdalar response during processing new positive words vs. known words was blunted in healthy PCLO+ carriers and in MDD patients irrespective of genotype, which may indicate that signalling of salient novel information does not occur to the same extent in PCLO+ carriers and MDD patients. The PCLO risk allele may increase vulnerability for MDD by modulating local brain function with regard to responsiveness to salient stimuli (i.e. insula) and processing novel negative information. Also, depression-specific effects of PCLO on dorsal striatal activation during negative word encoding and the absence of amygdalar salience signalling for novel positive information further suggest a role of PCLO in symptom maintenance in MDD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cytoskeletal Proteins / genetics*
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Major / genetics*
  • Depressive Disorder, Major / physiopathology*
  • Emotions* / drug effects
  • Female
  • Genetic Predisposition to Disease*
  • Gyrus Cinguli / pathology
  • Gyrus Cinguli / physiopathology
  • Health*
  • Humans
  • Male
  • Memory* / drug effects
  • Neostriatum / pathology
  • Neostriatum / physiopathology
  • Neuropeptides / genetics*
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Task Performance and Analysis

Substances

  • Cytoskeletal Proteins
  • Neuropeptides
  • PCLO protein, human
  • Serotonin Uptake Inhibitors

Grants and funding

The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (Zon-Mw, grant number 10-000-1002) and is supported by participating universities and mental health care organizations: VU University Medical Center, GGZ inGeest, Arkin, Leiden University Medical Center, GGZ Rivierduinen, University Medical Center Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Scientific Institute for Quality of Healthcare (IQ healthcare), Netherlands Institute for Health Services Research (NIVEL), Netherlands Institute of Mental Health and Addiction (Trimbos Institute), the Center for Medical Systems Biology (CSMB, NWO Genomics), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI –NL), and VU University’s institutes for Health and Care Research (EMGO+) and Neuroscience Campus Amsterdam (NCA). The genotyping of the samples was provided through the Genetic Association Information Network (GAIN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.